Sponsors
The bill increases oversight to reduce national‑security risks from drugs tied to PRC affiliations and improves supply‑chain transparency, but it risks disrupting access, raising drug costs, and imposing compliance and rights‑related burdens on companies and health systems.
Patients and health systems will face reduced exposure to drugs whose sponsors are affiliated with the PRC/CCP/PLA because FDA/CBP oversight may block or flag products tied to those affiliations.
Hospitals and health systems will gain greater supply‑chain transparency because FDA must review past and new applications and share a list of affected drugs with CBP, helping procurement and risk management.
Drug sponsors/holders who can demonstrate disaffiliation or sell to unaffiliated buyers within a set timeframe will retain a regulatory pathway to preserve patient access rather than face automatic removal.
Patients (including those with chronic conditions), Medicaid beneficiaries, and hospitals could face drug shortages or reduced access if FDA blocks approvals or CBP detains/destroys imported drugs tied to affiliated sponsors.
Patients and taxpayers may pay higher drug prices if supply disruptions or fewer eligible manufacturers reduce competition for affected products.
U.S. drug importers, hospitals, and sponsors will incur compliance, transactional, and potentially litigation costs (e.g., sales within 180 days, affiliation disputes).
Based on analysis of 2 sections of legislative text.
Requires FDA/HHS to identify sponsors affiliated with PRC/CCP/PLA, bars approvals and imports tied to those sponsors, and funds implementation with $5M.
Introduced April 16, 2026 by Thomas Bryant Cotton · Last progress April 16, 2026
Directs the HHS Secretary, through FDA and coordinating with HHS Office of National Security, to screen drug applications to identify sponsors affiliated with the People’s Republic of China, the Chinese Communist Party, or the People's Liberation Army. It bars FDA approval of new applications from identified affiliated sponsors, requires FDA to give Customs and Border Protection a list of drugs tied to those sponsors, and directs CBP to refuse and destroy (not export) imports of those drugs unless narrow exceptions apply. The bill funds these activities with a one-time authorization of $5 million, available until expended. The law applies immediately on enactment to applications submitted on or after that date and also directs review of applications submitted from January 1, 2016 through the day before enactment. It creates procedural safeguards for sponsors to contest affiliation findings, show they are no longer affiliated, or sell approved applications within 180 days, and allows CBP to waive import refusal when FDA finds refusal would cause or worsen a U.S. drug shortage.